Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EirGenix, Inc.

http://www.eirgenix.com

Latest From EirGenix, Inc.

Zydus Launches First Kadcyla Biosimilar in India At Sharp Discount

Zydus Cadila’s launch of the world’s first biosimilar to Roche’s breast cancer drug Kadcyla in India at an 80% discount to the original's listed price is expected to improve access, and follows its pioneering launch of an adalimumab biosimilar and a NASH therapy.

India Biosimilars

Zydus Launches First Kadcyla Biosimilar in India At Sharp Discount

Zydus Cadila’s launch of the world’s first biosimilar to Roche’s breast cancer drug Kadcyla in India at an 80% discount to the original's listed price is expected to improve access, and follows its pioneering launch of an adalimumab biosimilar and a NASH therapy

India Biosimilars

EirGenix Makes Progress With Trastuzumab Biosimilar

Taiwan’s EirGenix has made progress with its trastuzumab biosimilar for breast cancer, EG12014, announcing positive Phase III clinical results for the Herceptin equivalent. 

Biosimilars Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Contract Manufacturing Organization
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register